While regulatory bodies and pharmaceutical companies are discussing potential solutions to the drug shortages, societies such as the American Diabetes Association are providing guidelines to assist with alternative treatment options for patients with type 2 diabetes mellitus as well as guidelines to assist with dosage changes to be made while GLP-1 therapies are low in stock
Slide from Katherine Tuttles presentation, during FLOW session, 61st European Renal Association Congress Conclusion The FLOW trial showed that semaglutide significantly decreased the risk of progression of kidney disease in T2DM, without significant increases in serious adverse events
Patients with and without anti-tesamorelin IgG antibodies had similar mean reductions in visceral adipose tissue (VAT) and IGF-1 response suggesting that the presence of antibodies did not alter the efficacy of tesamorelin
Research has demonstrated its effectiveness across tendons, ligaments, muscle, bone, and gut tissue
Physicians may prescribe either for off-label uses, but coverage complications arise
